Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members, the association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources.

Member benefits exclusive access and discounts

As a Swiss Biotech Association member, you profit from our engagement with national and international stakeholders, receive privileged information, share knowledge, improve your network and optimize business efficiency. Get more visibility and receive discounts at events, favorable rates with business solution providers and for promoting your company.

Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome.

Indicaton

Therapeutic indications

Type of product

Table

You may also be interested in

nizubaglustat

Morphomer NLRP3-ASC

Anti-NLRP3-ASC antibody